Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Verónica Outeiriño-Iglesias"'
Autor:
Verónica Outeiriño-Iglesias, Eva Vigo, C. Rodríguez-Valencia, Miriam López-Álvarez, Julia Serra, Pío González
Publikováno v:
Clinical Oral Implants Research. 28:e91-e100
Objective The present work proposes the shark teeth as a new source of bioapatites for bone filler applications in maxillary sinus elevation, periodontal regeneration or implants placement. This abundant fishing by-product provides an improved hydrox
Autor:
Pilar Santisteban, Marina Romaní-Pérez, Lucas C. González-Matías, Verónica Outeiriño-Iglesias, Eva Vigo, Federico Mallo, Christian M. Moya
Publikováno v:
Endocrinology. 156:3559-3569
Diabetes alters microvascular function in the vascular beds of organs, including the lungs. Cardiovascular complications of pulmonary vascular affectation may be a consequence of the overactivation of the vasoconstrictive and proliferative components
Autor:
Manuel Gil-Lozano, Verónica Outeiriño-Iglesias, Eva Vigo, Federico Mallo, Marina Romaní-Pérez, Lucas C. González-Matías
Publikováno v:
Endocrinology. 154:1144-1155
The glucagon-like peptide-1 receptor (GLP-1R) is found in a variety of tissues outside of the pancreas. For example, GLP-1R is expressed in the lung, where it has been implicated in the regulation of the lipid fraction of surfactants, suggesting it f
Autor:
Verónica Outeiriño-Iglesias, Eva Vigo, Federico Mallo, Marina Romaní-Pérez, Lucas C. González-Matías
Publikováno v:
Endocrinology. 156(11)
Control of estrous cycle and reproductive capacity involves a large number of central and peripheral factors, integrating numerous nutritional and metabolic signals. Here we show that glucagon-like peptide-1 (GLP-1), a peptide with anorexigenic and i
Autor:
Verónica Outeiriño-Iglesias, Marina Romaní-Pérez, Eva Vigo, Patricia L. Brubaker, Lucas C. González-Matías, Federico Mallo, Manuel Gil-Lozano
Publikováno v:
Endocrinology. 155(7)
Glucagon-like peptide-1 (GLP-1) and the GLP-1 receptor agonist, exendin-4 (Ex-4), potently stimulate hypothalamic-pituitary-adrenal (HPA) axis activity after either central or peripheral administration. Because several GLP-1 derivative drugs, includi
Autor:
Patricia L. Brubaker, Lucas C. González-Matías, Marina Romaní-Pérez, Federico Mallo, Verónica Outeiriño-Iglesias, Eva Vigo, Manuel Gil-Lozano
Publikováno v:
American journal of physiology. Endocrinology and metabolism. 304(10)
Exendin-4 (Ex-4) is a natural agonist of the glucagon-like peptide-1 (GLP-1) receptor, currently being used as a treatment for type 2 diabetes mellitus due to its insulinotropic properties. Previous studies have revealed that acute administration of